Kyverna Therapeutics, Inc. (KYTX) Stock Price & Analysis
Kyverna Therapeutics, Inc. (KYTX) rose 1.65% to USD 7.41 as of July 25, 2026 at 03:03 UTC, according to Nexqual real-time market data.
KYTX last closed at USD 7.29; the session ranged USD 7.11–7.55 on volume of 850,732 shares. Market capitalization is $450.49M, with a 52-week range of USD 2.8–13.67 (NMS). Source: Nexqual, July 25, 2026 at 03:03 UTC.
Key Statistics (as of July 25, 2026 at 03:03 UTC)
| Price | USD 7.41 |
|---|---|
| Change | ▲ 1.65% (up) |
| Previous Close | USD 7.29 |
| Open | USD 7.29 |
| Day Range | USD 7.11 – 7.55 |
| 52-Week Range | USD 2.8 – 13.67 |
| Volume | 850,732 shares |
| Market Cap | $450.49M |
| Exchange | NMS |
Technical Analysis (KYTX)
Nexqual's technical model rates KYTX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.77 (neutral) |
| vs SMA50 | Below (USD 8.37) |
| MACD | -0.33 (negative) |
Analyst Ratings (KYTX)
Wall Street analysts rate KYTX "None" based on 5 analysts, with a mean price target of USD 30.4 (range USD 25–33), per Nexqual as of July 25, 2026 at 03:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 30.4 |
| High Target | USD 33 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (KYTX)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.68 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.8 vs est -0.86 ▲ beat |
| 2025-09-30 | USD -0.85 vs est -0.95 ▲ beat |
| 2025-06-30 | USD -0.97 vs est -1.04 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financials & Fundamentals (KYTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -74.55% |
| Debt / Equity | 17.26 |
| Current Ratio | 8.15 |
| Total Cash | $236.45M |
| Total Debt | $33.76M |
| Free Cash Flow | $-93.76M |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Financial Health Score (KYTX)
Nexqual rates Kyverna Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $236M cash vs $34M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$150M |
| Efficiency | Critical — ROE -75%, ROA -39.5% |
Ownership (KYTX)
| Insider Ownership | +7.10% |
|---|---|
| Institutional Ownership | +75.44% |
| Shares Outstanding | 60.80M |
| Float | 35.55M |
| Short % of Float | +13.99% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
Leadership (KYTX)
Kyverna Therapeutics, Inc. is led by Warner Biddle (age 58), CEO & Director, per Nexqual as of July 25, 2026 at 03:03 UTC.
| CEO & Director | Warner Biddle (age 58) |
|---|---|
| Chief Financial Officer | Gregory Martini (age 36) |
| Chief Technology Officer | Mayo Pujols (age 55) |
Major Backers & Investors (KYTX)
Notable institutional backers of Kyverna Therapeutics, Inc. include GordonMD Global Investments LP, Gilead Sciences Inc, Bain Capital Life Sciences Investors, LLC, according to Nexqual as of July 25, 2026 at 03:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GordonMD Global Investments LP | 6.98% |
| Gilead Sciences Inc | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 5.12% |
| AIGH Capital Management LLC | 3.29% |
| Deerfield Management Company, L.P | 3.29% |
| Price (T.Rowe) Associates Inc | 2.56% |
| T. Rowe Price | 1.88% |
| Balyasny Asset Management LP | 1.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.8% |
Source: Nexqual, July 25, 2026 at 03:03 UTC.
From Kyverna Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
- Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
- The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
- It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | USD 26.78 | ▼ 1.65% |
| CGON | CG Oncology, Inc. | USD 69.32 | ▲ 0.01% |
| ARTV | Artiva Biotherapeutics, Inc. | USD 10.03 | ▲ 0.1% |
| CABA | Cabaletta Bio, Inc. | USD 2.69 | ▼ 2.18% |
| JANX | Janux Therapeutics, Inc. | USD 15.33 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:03 UTC. This page is informational and not investment advice.